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In 28 patients with acute myocardial infarction, the release pattern of 2,3-butanediol (BD), a product of
intermediary metabolism, and creatine kinase activity (CK) in blood were compared. Whereas CKat entry
was low in all patients, the BD level was elevated in 18 (64%). However, BD returned to normal levels during
the next 24 h whereas CK increased. The BD level at entry did not allow differentiation between patients with
transmural or non-transmural infarction; it was independent of clinical findings and biochemical parameters.
We suggest that, in patients with acute myocardial infarction, elevated levels of BD originates from myo-
cardial metabolism. Whether it reflects ongoing ischaemia or reperfusion of the infarcted area remains
unresolved.
Introduction
In the early phase of myocardial infarction, no
biochemical parameter for myocardial ischaemia is
known in the peripheral venous blood. Elevation of
plasma creatine kinase occurs late and indicates
myocardial injury or cell necrosis. A biochemical
parameter for ischaemia however could be import-
ant for stratifying patients with acute chest pain.
2,3-butanediol (BD) is a product of intermediary
metabolism; its precursors are pyruvate, acetalde-
hyde and acetoin'1'2'. In his studies of the enzymatic
synthesis and breakdown of acetoin in the animal
organism, Jarnefelt has shown that, under anaero-
bic conditions, the formation of BD is accelerated'31.
In a preliminary study we found elevated levels
of BD in some patients with acute myocardial
infarction.
We report a prospective study of 28 patients with
acute myocardial infarction. In addition to conven-
tional clinical, electrocardiographic and enzymatic
techniques we performed frequent serial determi-
nations of BD to assess its release pattern.
Patients and methods
Of 121 consecutive patients with chest pain who
were admitted to the coronary care unit, 21 men and
7 women (age 42 to 84 years) were included in the
prospective study. All 28 patients had typical chest
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pain of at least 30 min duration, which had occurred
within the preceding 6 h. Serial electrocardiograms
showed in all cases either Q wave evolution or
typical S-T wave changes. Increase of CK activity
during the first day was noted in 22 patients. As a
reference group, we determined BD in 23 patients
with stable angina pectoris (aged 29-78 years).
For the analysis of 2,3-butanediol, 10 ml samples
of venous blood were taken at 2,4,6,9,12 and 24 h
after the onset of pain. The blood was deproteinized
immediately with sulphuric and tungstic acid. The
supernatant was frozen at — 20 °C and stored. The
samples were analysed according to the method
described by Happold and Spencer'4' and
Westerfeld'51.2,3-butanediol in the supernatant was
oxidized to diacetyl with bromide and ferrichloride;
diacetyl was reacted with 2,4-dinitrophenylhydra-
zine. The precipitated hydrazone was filtered and
determined colorimetrically. The relative coef-
ficient of variation was less than 5%; normal levels
are below 0029 mmol I"1. The results were obtain-
able within 8 h. CK activity was measured with a
commercially available diagnostic kit (Merck);
normal values are below 80 U1" ' .
Results are expressed as the mean±SD (SEM
where noted). Unpaired Student's r-test was used
for statistical analysis.
Results
In a group of 28 patients with acute myocardial
infarction, BD showed a release pattern contrast-
ing to the rise of CK during the first 24 h (Fig. 1).
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At entry, 18 of 28 patients had elevated levels
of BD, 0087 ±0036 mmoir 1 (range 0055-
0-188 mmol I"1), which decreased to normal
levels within 24h, 0025±0-015 mmoir 1 . In 10
other patients, BD was found to be normal at
entry, 0012±0006 mmol I"1 (range 0006-
0026 mmol 1"'); in eight it remained normal during
the 24 h, whereas in two minor changes were noted.
No significant difference in history (unstable angina
pectoris and old myocardial infarction), clinical
presentation at entry (Killip), duration of chest pain
or need for antiarrhythmic therapy was found
between patients with high or low levels of BD. The
release of BD was independent of time of admission
and history of alcohol consumption. In 23 patients
with stable angina pectoris the mean value of
BD was 0015±0005mmol 1"' (range 0-008-
0-029 mmol I"1).
Twenty-one patients showed a typical rise in CK
during the first 24 h; CK was higher in transmural
than in non-transmural infarction. No or little rise
in CK was found in four patients with low BD and
in three patients with high BD at entry; they all
had non-transmural infarction. There was no direct
relationship between BD level and CK activity;
however patients with high BD at entry showed a
non-significantly higher level of CK 9 h after the
onset of chest pain. In addition, patients with
transmural infarction had a significantly higher BD
level at 12 h than patients with non-transmural
infarction (P< 0-02).
Two patients died; both were in cardiogenic
shock on admission and both had transmural
infarction. Their BD levels were 0-017 mmol I"1 and
0-049 mmoir1 .
Discussion
BD at entry in 28 patients with acute myocardial
infarction was found to be significantly different
from BD in a group of 23 patients with stable
angina pectoris (P < 0-001). However, a difference
in release pattern was noted within the group of
acute myocardial infarction patients. In 18 of 28
patients (64%), BD was elevated at entry and
returned to normal within 24 h; in 10 patients (36%)
BD remained normal during the study period. This
different pattern was related neither to the localiz-
ation or extent of the infarction nor to clinical
parameters. However at 12 h after the onset of pain,
BD was significantly higher in patients with trans-
mural infarction (Fig. 1). We suggest that BD is a
product of ischaemic myocardial metabolism which
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Figure I 2,3-butanediol (a) and creatine kinase (b) during
the first 24 h in 28 patients with acute myocardial infarction
(mean±SEM). Open area: transmural infarction; dashed
area: non-transmural infarction.
is released early into the peripheral circulation,
unlike CK, which is found in blood only after some
hours. This is supported by the study of Jarnefelt
who showed that BD is produced in heart muscle
and that production is increased under anaerobic
conditions'31. We suppose that BD crosses the cellu-
lar membrane early in the course of ischaemia, as
does lactate which can be found in the coronary
sinus but not in the peripheral blood'61. Both metab-
olites have a low molecular weight. However, it still
remains unresolved whether elevated BD at entry
indicates ongoing ischaemia or washout of ischae-
mic metabolites by natural reperfusion of the
infarcted area. As evolution of a myocardial infarc-
tion is considered to be a dynamic process171, the
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explanation is even more difficult. The finding that
in patients with transmural infarction BD remains
elevated during the first 12 h in comparison to
non-transmural infarction could however be due to
dynamic alteration of myocardial metabolism and
perfusion. In patients with non-transmural infarc-
tion this dynamic process would be of shorter
duration with earlier reperfusion; however, one can
not exclude the possibility that in these patients the
ischaemic area at the onset of pain is large enough to
produce substantial quantity of BD. Indeed in 11
of 19 patients with non-transmural infarction, BD
was high at entry, 0-083±0-021 mmol I"1 (range
0056-0-114 mmoir1) .
Different patterns of BD could also be due to
different metabolism and excretion of the metab-
olite itself. However this seems to be less likely,
although little is known about metabolism and ex-
cretion. Soling et al. concluded from their rat study
that approximately 80% of infused BD was
absorbed by the peripheral tissue within 2—4 b18'.
From their cat studies, Dawson and Hullin came to
the conclusion that BD was rapidly metabolized as
a first step (up to 90% within the first hours); the
second step would be slow1'1. According to obser-
vations by Westerfeld and Berg, urinary excretion is
minor19'.
Elevated levels of BD are also found in patients
with hepatic or uraemic coma'101; rising blood
glucose in diabetics is accompanied by a rising level
of BD1"1. However no patient of our study had renal
or hepatic insufficiency or a metabolic disorder.
Elevated alcohol intake could be excluded from the
patients' history. They also had no pulmonary
embolism or perimyocarditis.
The findings of our study suggest that elevated
BD in blood of patients with acute myocardial
infarction originates from ischaemic myocardial
metabolism. Whether it indicates ongoing ischae-
mia or reperfusion still remains unresolved. Further
studies are needed to support our results and to
clarify their relevance for managing patients with
acute myocardial infarction. New and rapid labora-
tory methods are needed.
We are indebted to Miss Astrid Gysin for technical assist-
ance and to the nursing staff of the intensive care unit for
obtaining blood samples.
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